Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited Ordinary Shares
(NY:
TEVA
)
39.98
-0.41 (-1.02%)
Delayed Quote
Updated: 3:03 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
May 18, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
May 18, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.
↗
May 15, 2026
The market's rediscovery of Teva Pharmaceuticals remains ongoing.
Via
The Motley Fool
Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right.
↗
May 14, 2026
Teva's turnaround is real -- and may not be over.
Via
The Motley Fool
Teva to Present at the BofA Securities Health Care Conference
May 04, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
April 30, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?
↗
April 30, 2026
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
Via
The Motley Fool
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
April 29, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
April 29, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.
↗
April 27, 2026
That's when its first-quarter results will be published.
Via
The Motley Fool
3 Catalysts That Could Send Teva Stock to $40 and Beyond
↗
April 18, 2026
This once-beaten-down pharma stock remains an intriguing turnaround story.
Via
The Motley Fool
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
April 15, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
April 14, 2026
Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
April 07, 2026
Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
March 31, 2026
In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...
Via
MarketMinute
Topics
ETFs
Intellectual Property
Stocks
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
March 30, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
March 26, 2026
The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...
Via
MarketMinute
Topics
Intellectual Property
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
March 26, 2026
March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of...
Via
Finterra
Topics
Economy
Intellectual Property
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
↗
March 22, 2026
Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide.
Via
The Motley Fool
Teva Releases Q1 2026 Aide Memoire
March 19, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
March 19, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism
March 18, 2026
By Finterra Editorial TeamMarch 18, 2026 Introduction In the high-stakes world of global alternative asset management, one name looms larger than the rest: Blackstone Inc. (NYSE: BX). As of March 18,...
Via
Finterra
Topics
Artificial Intelligence
Economy
Energy
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
↗
March 13, 2026
This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
↗
March 13, 2026
This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
March 10, 2026
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:...
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
The 3 Best Stocks to Invest $1,000 in Right Now
↗
March 06, 2026
These three high-quality stocks have ample growth potential.
Via
The Motley Fool
Topics
Artificial Intelligence
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today
↗
March 04, 2026
Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.
Via
The Motley Fool
Topics
Intellectual Property
Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding
↗
March 04, 2026
Duquesne Family Office's billionaire boss meaningfully pared down two high-flying stocks in the fourth quarter and made a $301 million wager on a popular sector-based exchange-traded fund (ETF).
Via
The Motley Fool
Topics
Artificial Intelligence
ETFs
Retirement
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
March 03, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
March 03, 2026
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...
Via
Finterra
Topics
Economy
Initial Public Offering
Retirement
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
